ProLynx Awarded NSF Supplement for Inner Ear Hydrogel System
ProLynx has been awarded a technology enhancement for commercial partnerships supplement to its Phase 2 grant from the National Science Foundation.
The supplement will provide funds for in vivo imaging studies of the company’s hydrogel, which is being developed to serve as a carrier for an inner ear disorders treatment, the San Francisco, Calif., devicemaker said Tuesday.
ProLynx’s initial study objective consists of determining the residence times and biodegradation rates of the delivery system in the middle ear. The company will then attach drugs to the hydrogel and evaluate the system’s drug release rates and efficacy.
ProLynx develops drug delivery systems for half-life extension of proteins, peptides and small molecules. — Jason Scott